At a glance
ClinicalIndex Comparison Record- ✓Female patient at least 18 years old
- ✓Histologically confirmed recurrent or persistent clear cell carcinoma of ovary, endometrium, cervix, vagina, or vulva
- ✓≥50% clear cell histology in mixed carcinoma; local gynecologic pathologist review required
- ✓WT-1 negative for ovarian cancer cases only
- ✕≥6 prior lines of chemotherapy
- ✕Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
- ✕Prior anticancer therapy within 21 days or <5 times half-life, whichever is shorter
- ✕Contraindication to chemotherapy, immunotherapy, or anti-angiogenic therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)
In Brief
A Phase 2 clinical trial evaluating Dostarlimab, Bevacizumab, and 4 other interventions for Ovarian Neoplasms and 5 related conditions. Currently recruiting, targeting 198 participants across 27 sites in 7 countries.
Detailed Summary
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma. 198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio. 1. Group A: Dostarlimab monotherapy * First 3 cycles: Dostalimab 500mg every 3 weeks, IV * 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV 2. Group B: Dostarlimab + Bevacizumab combination therapy * First 3 cycles: Dostalimab 500mg every 3 weeks, IV * 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV * Bevacizumab administered IV at 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity 3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
Study Details
Timeline
Interventions
Intravenous (IV) infusion
Intravenous (IV) infusion
Intravenous (IV) infusion
Intravenous (IV) infusion
Intravenous (IV) infusion
Intravenous (IV) infusion